| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi, J Yuan, ... Cancer discovery 3 (9), 1030-1043, 2013 | 600 | 2013 |
| Studying clonal dynamics in response to cancer therapy using high-complexity barcoding HC Bhang, DA Ruddy, V Krishnamurthy Radhakrishna, JX Caushi, ... Nature medicine 21 (5), 440-448, 2015 | 519 | 2015 |
| Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma R Rahal, M Frick, R Romero, JM Korn, R Kridel, F Chun Chan, B Meissner, ... Nature medicine 20 (1), 87-92, 2014 | 396 | 2014 |
| CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions DM Munoz, PJ Cassiani, L Li, E Billy, JM Korn, MD Jones, J Golji, ... Cancer discovery 6 (8), 900-913, 2016 | 377 | 2016 |
| Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss H Liu, J Golji, LK Brodeur, FS Chung, JT Chen, RS deBeaumont, ... Nature medicine 25 (1), 95-102, 2019 | 251 | 2019 |
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia, D Timonina, E Labrot, ... Oncogene 38 (37), 6399-6413, 2019 | 178 | 2019 |
| A chemical genetics approach for the functional assessment of novel cancer genes Q Zhou, A Derti, D Ruddy, D Rakiec, I Kao, M Lira, V Gibaja, HM Chan, ... Cancer research 75 (10), 1949-1958, 2015 | 130 | 2015 |
| FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors F Li, H Huynh, X Li, DA Ruddy, Y Wang, R Ong, P Chow, S Qiu, A Tam, ... Cancer discovery 5 (4), 438-451, 2015 | 105 | 2015 |
| CHMP1A encodes an essential regulator of BMI1-INK4A in cerebellar development GH Mochida, VS Ganesh, MI De Michelena, H Dias, KD Atabay, ... Nature genetics 44 (11), 1260-1264, 2012 | 104 | 2012 |
| A homozygous mutation in the tight-junction protein JAM3 causes hemorrhagic destruction of the brain, subependymal calcification, and congenital cataracts GH Mochida, VS Ganesh, JM Felie, D Gleason, RS Hill, KR Clapham, ... The American Journal of Human Genetics 87 (6), 882-889, 2010 | 104 | 2010 |
| Inhibition of casein kinase 1 alpha prevents acquired drug resistance to Erlotinib in EGFR-mutant non–small cell lung cancer AB Lantermann, D Chen, K McCutcheon, G Hoffman, E Frias, D Ruddy, ... Cancer Research 75 (22), 4937-4948, 2015 | 60 | 2015 |
| Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models HQ Wang, E Halilovic, X Li, J Liang, Y Cao, DP Rakiec, DA Ruddy, S Jeay, ... Elife 6, e17137, 2017 | 56 | 2017 |
| Hyperactivation of MAPK signaling is deleterious to RAS/RAF-mutant melanoma GP Leung, T Feng, FD Sigoillot, FC Geyer, MD Shirley, DA Ruddy, ... Molecular Cancer Research 17 (1), 199-211, 2019 | 55 | 2019 |
| The lineage determining factor GRHL2 collaborates with FOXA1 to establish a targetable pathway in endocrine therapy-resistant breast cancer KJ Cocce, JS Jasper, TK Desautels, L Everett, S Wardell, T Westerling, ... Cell reports 29 (4), 889-903. e10, 2019 | 51 | 2019 |
| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov. 2013; 3: 1030–1043. doi: 10.1158/2159-8290 M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi, J Yuan, ... Cd-13-0142.[Abstract][CrossRef][Google Scholar], 0 | 42 | |
| BRAF-inhibitor associated MEK mutations increase RAF-dependent and-independent enzymatic activity CM Emery, KA Monaco, P Wang, M Balak, A Freeman, J Meltzer, ... Molecular Cancer Research 15 (10), 1431-1444, 2017 | 24 | 2017 |
| A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts AC Palmer, D Plana, H Gao, JM Korn, G Yang, J Green, X Zhang, ... Cancer research 80 (19), 4278-4287, 2020 | 14 | 2020 |
| In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling Z Jagani, G Chenail, K Xiang, G Bushold, HEC Bhang, A Li, GN Elliott, ... Biorxiv, 812628, 2019 | 10 | 2019 |
| RAF-mutant melanomas differentially depend on ERK2 over ERK1 to support aberrant MAPK pathway activation and cell proliferation MS Crowe, T Zavorotinskaya, CF Voliva, MD Shirley, Y Wang, DA Ruddy, ... Molecular Cancer Research 19 (6), 1063-1075, 2021 | 3 | 2021 |
| Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts T Feng, J Golji, A Li, X Zhang, DA Ruddy, DP Rakiec, FC Geyer, J Gu, ... Molecular Cancer Therapeutics 18 (12), 2421-2432, 2019 | 3 | 2019 |
